GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Altimmune Inc (LTS:0A4C) » Definitions » Valuation Rank

Altimmune (LTS:0A4C) Valuation Rank


View and export this data going back to 2020. Start your Free Trial

What is Altimmune Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Altimmune Valuation Rank Related Terms

Thank you for viewing the detailed overview of Altimmune's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Altimmune (LTS:0A4C) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Altimmune Inc (LTS:0A4C) » Definitions » Valuation Rank
Comparable Companies
HRTX OABI ALLO CABA TRDA LXEO NWBO ADPT OLMA YMAB OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
ALT:USA ALT1:Mexico 3G0:Germany
Address
910 Clopper Road, Suite 201S, Gaithersburg, MD, USA, 20878
Website
https://www.altimmune.com
Altimmune Inc is engaged on developing treatments for obesity and liver diseases. The Company's pipeline includes next generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.